Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients

Journal of Crohn's and Colitis

Volumn 7, Issue 12, 2013, Pages

  Miyoshi, Jun ^a,b   Matsuoka, Katsuyoshi ^a   Inoue, Nagamu ^a   Hisamatsu, Tadakazu ^a   Ichikawa, Riko ^a   Yajima, Tomoharu ^a   Okamoto, Susumu ^a   Naganuma, Makoto ^a   Sato, Toshiro ^a   Kanai, Takanori ^a   Ogata, Haruhiko ^a   Iwao, Yasushi ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

Author keywords

Mucosal healing; Tacrolimus; Ulcerative colitis

Indexed keywords

INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; COLON MUCOSA; COLON RESECTION; COLONOSCOPY; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPY; EVENT FREE SURVIVAL; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOMAGNESEMIA; INDUCTION CHEMOTHERAPY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; ULCER HEALING; ULCERATIVE COLITIS;

MUCOSAL HEALING; TACROLIMUS; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; COLONOSCOPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEROIDS; TACROLIMUS; TIME FACTORS; WOUND HEALING; YOUNG ADULT;

EID: 84887613287     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.04.018     Document Type: Article

References (20)

1. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2:1041-1048.
2. Baron J.H., Connell A.M., Kanaghinis T.G., Lennard-Jones J.E., Jones A.F. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962, 2:441-443.
3. Lichtiger S., Present D.H., Kornbluth A., Gelernt I., Bauer J., Galler G., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845.
4. Fellermann K., Ludwig D., Stahl M., David-Walek T., Stange E.F. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998, 93:1860-1866.
5. Fellermann K., Tanko Z., Herrlinger K.R., Witthoeft T., Homann N., Bruening A., et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002, 8:317-324.
6. Hogenauer C., Wenzl H.H., Hinterleitner T.A., Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003, 18:415-423.
7. Baumgart D.C., Wiedenmann B., Dignass A.U. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17:1273-1281.
8. Ogata H., Matsui T., Nakamura M., Iida M., Takazoe M., Suzuki Y., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255-1262.
9. Ogata H., Kato J., Hirai F., Hida N., Matsui T., Matsumoto T., et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012, 18:803-808.
10. Schmidt K.J., Herrlinger K.R., Emmrich J., Barthel D., Koc H., Lehnert H., et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther 2013, 37:129-136.
11. Herrlinger K.R., Koc H., Winter S., Teml A., Stange E.F., Fellermann K., et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther 2011, 89:422-428.
12. Baumgart D.C., Pintoffl J.P., Sturm A., Wiedenmann B., Dignass A.U. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 2006, 101:1048-1056.
13. Ng S.C., Arebi N., Kamm M.A. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:129-134.
14. Benson A., Barrett T., Sparberg M., Buchman A.L. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008, 14:7-12.
15. Yamamoto S., Nakase H., Mikami S., Inoue S., Yoshino T., Takeda Y., et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008, 28:589-597.
16. Ziring D.A., Wu S.S., Mow W.S., Martin M.G., Mehra M., Ament M.E. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007, 45:306-311.
17. Watson S., Pensabene L., Mitchell P., Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 2011, 17:22-29.
18. Yamamoto S., Nakase H., Matsuura M., Masuda S., Inui K., Chiba T. Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol 2011, 45:526-530.
19. Naganuma M., Ichikawa H., Inoue N., Kobayashi T., Okamoto S., Hisamatsu T., et al. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010, 45:936-943.
20. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.